Health Care & Life Sciences » Pharmaceuticals | Marinus Pharmaceuticals Inc.

Marinus Pharmaceuticals Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
10,037.10
49,720.00
56,196.00
30,100.00
53,392.00
72,725
Other Current Assets
1,761.40
428.00
1,571.00
199.00
978.00
1,215
Total Current Assets
11,798.50
50,148.00
57,767.00
30,299.00
54,370.00
73,940
Net Property, Plant & Equipment
16.10
44.00
31.00
1,148.00
1,338.00
1,294
Total Investments and Advances
-
-
1,488.00
-
4,964.00
-
Other Assets
9.40
21.00
362.00
-
-
-
Total Assets
11,823.90
50,213.00
59,648.00
31,447.00
60,672.00
75,234
ST Debt & Current Portion LT Debt
-
-
2,128.00
3,500.00
-
Accounts Payable
-
-
-
-
927.00
Other Current Liabilities
2,365.80
2,039.00
5,307.00
4,584.00
1,617.00
Total Current Liabilities
2,365.80
2,039.00
7,435.00
8,084.00
2,544.00
Long-Term Debt
-
7,000.00
5,236.00
1,743.00
-
Other Liabilities
-
20.00
56.00
141.00
120.00
Total Liabilities
2,365.80
9,059.00
12,727.00
9,968.00
2,664.00
Common Equity (Total)
60,382.00
41,154.00
46,921.00
21,479.00
58,008.00
Total Shareholders' Equity
9,458.20
41,154.00
46,921.00
21,479.00
58,008.00
Total Equity
9,458.20
41,154.00
46,921.00
21,479.00
58,008.00
Liabilities & Shareholders' Equity
11,823.90
50,213.00
59,648.00
31,447.00
60,672.00
Preferred Stock (Carrying Value)
69,840.20
-
-
-
-

About Marinus Pharmaceuticals

View Profile
Address
170 North Radnor Chester Road
Radnor Pennsylvania 19087
United States
Employees -
Website http://www.marinuspharma.com
Updated 07/08/2019
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded by Geoffrey E.